LONDON, Dec. 10,
2024 /PRNewswire/ -- Virax Biolabs Group Limited
(NASDAQ: VRAX) ("Virax" or the "Company"), an innovative
biotechnology company focused on the detection of immune responses
and diagnosis of viral diseases, today announced that it has
entered into a non-exclusive distribution agreement with French
company Tebubio to expand the distribution of its ImmuneSelect
Research Use portfolio into countries in the European Union, as
well as in Norway and Switzerland.
"We are honored to announce this agreement with Tebubio, who
will prove to be instrumental in increasing the accessibility of
ImmuneSelect for life science institutions across a crucial market
such as Europe," said
James Foster, CEO of Virax
Biolabs. "This agreement further strengthens our ongoing
efforts to advance immune profiling technology and supports a
growing need for comprehensive insights into immune health status
through ImmuneSelect."
"This collaboration with Virax holds a great significance for
our company as it demonstrates our commitment to innovative
diagnostic tools such as ImmuneSelect," said Romain Cordonnier-Goulay, CSO of
Tebubio. "Our strong distribution networks and relations across
Europe will help ImmuneSelect
become more accessible to customers to help with their research
needs."
About ImmuneSelect
ImmuneSelect is the Company's portfolio of research products
dedicated to investigating adaptive immunity. Products within the
ImmuneSelect brand are for research and investigational use only
and are not intended to be used as a diagnostics tool. The
ImmuneSelect portfolio includes peptide pools covering epitopes
from pathogens, optimized for the stimulation of T cells. The
initial offerings include pools for SARS-CoV-2, SARS-CoV-2 MHC-1
("CD8"), Lyme Disease, Cytomegalovirus ("CMV"), Respiratory
Syncytial Virus ("RSV") and Epstein-Barr Virus ("EBV"), which
continue to be regularly expanded. ImmuneSelect's Recombinant
Antibodies target cytokines and biomarkers, and they are available
in different versions unconjugated to be tested on a range of
applications including Flow Cytometry, ELISA and
ELISpot/Fluorospot. ImmuneSelect is affordable, easy to use, and is
compatible with most standard laboratory equipment.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology
company focused on the detection of immune responses to and
diagnosis of viral diseases. Virax Biolabs Group Limited is
currently developing T-Cell-based test technologies with the
intention of providing an immunology profiling platform. T-Cell
testing can be particularly effective in the diagnosis and
therapeutics of post-viral syndromes such as Long COVID and other
chronic conditions linked to immune dysregulation.
For more information, please
visit www.viraxbiolabs.com.
About Tebubio
We facilitate Life Sciences Research every day, contributing to
advance Science for a brighter future. Through our Tebubio local
offices located across Europe, we
support Life Sciences and Biotechnology Researchers with a unique,
holistic range of solutions to advance their projects faster. With
Tebubio, concentrate your efforts and accelerate what's most
important to you: Your Research.
For more information, please visit www.tebubio.com
Investor Relations Contact:
Russo Partners, LLC
Nic Johnson
12 West 27th Street
4th Floor
New York, NY 10001
M: 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-announces-agreement-with-tebubio-to-expand-distribution-of-immuneselect-across-the-european-union-norway-and-switzerland-302327093.html
SOURCE Virax Biolabs